The patch is for people with type 1 or type 2 diabetes who require mealtime insulin.
Recent Posts
- January, 2025CeQur Closes a $120M Equity Financing to Drive Commercial Growth
- June, 2024CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management
- June, 2021CeQur Appoints Rick Doubleday and Dr. Meret Gaugler to Board of Directors
- April, 2021CeQur Raises $115 Million Series C5
- June, 2020“High Treatment Satisfaction with 3-day Insulin Patch is Independent of Patient Demographics: A Post-Hoc Analysis” — a presentation at the American Diabetes Association 80th Scientific Sessions